Affiliation:
1. Center for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA
Abstract
Plazomicin is a recent U.S. Food and Drug Administration (FDA)-approved semisynthetic aminoglycoside. Its structure consists of a sisomicin scaffold modified by adding a 2(S)-hydroxy aminobutyryl group at the N1 position and a hydroxyethyl substituent at the 6′ position. These substitutions produced a molecule refractory to most aminoglycoside-modifying enzymes. The main enzyme within this group that recognizes plazomicin as substrate is the aminoglycoside 2′-N-acetyltransferase type Ia [AAC(2′)-Ia], which reduces the antibiotic’s potency. Designing formulations that combine an antimicrobial with an inhibitor of resistance is a recognized strategy to extend the useful life of existing antibiotics. We have recently found that several metal ions inhibit the enzymatic inactivation of numerous aminoglycosides mediated by the aminoglycoside 6′-N-acetyltransferase type Ib [AAC(6′)-Ib]. In particular, Ag+, which also enhances the effect of aminoglycosides by other mechanisms, is very effective in interfering with AAC(6′)-Ib-mediated resistance to amikacin. Here we report that silver acetate is a potent inhibitor of AAC(2′)-Ia-mediated acetylation of plazomicin in vitro, and it reduces resistance levels of Escherichia coli carrying aac(2′)-Ia. The resistance reversion assays produced equivalent results when the structural gene was expressed under the control of the natural or the blaTEM-1 promoters. The antibiotic effect of plazomicin in combination with silver was bactericidal, and the mix did not show significant toxicity to human embryonic kidney 293 (HEK293) cells.
Funder
National Institute of Health
National Institute on Minority Health and Health Disparities
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference68 articles.
1. Bad bugs, no drugs 2002–2020: Progress, challenges, and call to action;Boucher;Trans. Am. Clin. Climatol. Assoc.,2020
2. Multidrug-resistant Gram-negative bacilli: Infection control implications;Adler;Infect. Dis. Clin. N. Am.,2016
3. Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections;Bassetti;J. Antimicrob. Chemother.,2021
4. Perez, F., El Chakhtoura, N.G., Yasmin, M., and Bonomo, R.A. (2019). Polymyxins: To combine or not to combine?. Antibiotics, 8.
5. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: The prognostic significance of colistin resistance;Machuca;Int. J. Antimicrob. Agents,2019